Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 6.30 6.20 6.40 6.35 6.30 6.30 146,919 08:00:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 6.1 -0.0 0.1 78.8 29

Byotrol Share Discussion Threads

Showing 9251 to 9274 of 11750 messages
Chat Pages: Latest  374  373  372  371  370  369  368  367  366  365  364  363  Older
DateSubjectAuthorDiscuss
28/4/2020
17:00
Exactly afewbob-just a lightweight trying to deramp. Huge prospects here going forward. MMs will predictably spend a few days just feeding off the weak before they let it go again. With so much happening I don't think the company, or broker, are in a position to give forecasts, nor should mgmt even try at what is the most dynamic time of this company's life. Patience.
cumnor
28/4/2020
16:35
It’s the forward looking statement that counts.
a.fewbob
28/4/2020
16:34
How do??? How do you know that??????? Results were only to mid March you muppet.
a.fewbob
28/4/2020
16:30
They certainly dont seem to have used the massive opportunity presented by covid as much as I hoped. The markets remain unimpressed. There seems to be a lack of dynamism
brownson
28/4/2020
12:07
brownson, "market seems unimpressed" As expected, they missed expectations despite the huge increase in orders due to Covid19. Even though Expectations were EXCLUDING covid19, so excluding Covid19 sales. Actuals INCLUDE Covid19 sales. Period, expectations, actuals Revenue £6m, £6m Adj EBITDA £0.4m £0.25m Cash £2.6m, £1.7m https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf Cash balances have been declining for years.. fy2018 £3.85m fy2019 £2.8m H12020 £2.01m fy2020 £1.7m
sikhthetech
28/4/2020
11:45
Well I bought some more. That’s an extremely upbeat trading statement in a market which is booming and will continue to do so as this covid disease has brought hygiene to the forefront like never before. When procurement stop panic buying and start thinking more carefully they will see that BYOT product is absolutely fantastic!!
a.fewbob
28/4/2020
11:08
The market seems unimpressed.
brownson
28/4/2020
09:15
Any thoughts to why we didn't get a RNS on the 'massive' April deal they mention. As you say, all the heavy lifting has been done. Just a question of signing deals and selling. Well done to the company.
loafofbread
28/4/2020
08:54
Thanks for all your input 1gw,as you say very encouraging and downside risk medium/long term very low.Usual selling after the fact but 2021 figures should be stellar.
riddlerone
28/4/2020
08:03
Just mulling over the TU, I think it would be difficult to imagine a more positive business outlook. This has been reflected at least in part by finnCap raising their target price from 7p to 9p. Clearly it must be very difficult to quantify the outlook in terms of high-confidence revenue and profit expectations given the uncertainties, and perhaps the company felt that it was enough to make the qualitative statements given how positive they were. The company will have a chance to update on 1Q performance and 1H outlook when it publishes FY20 results and by then the supply chain capacity position and demand outlook for the rest of the year may be much clearer. It strikes me, in passing, that the statements below from the TU would not appear out of place in the marketing material for a sale of the company. “We continue to experience exceptional demand…” “…expecting to benefit significantly from a secular shift…” “…expect to generate record sales from products …in the first quarter of the year.” “…also working on a number of longer-term product supply contracts and technology licenses…̶1; “Byotrol has been positioning for such trends for many years and expects them to favour technologies like ours, presenting exceptional growth opportunities for the Group.” “We now expect FY2021 to be one of significant growth in both revenue and EBITDA.” “Our technologies are getting interest from all over the world now. We are increasingly well positioned for further growth post Covid19…”;
1gw
27/4/2020
23:02
Because they’ve been ridiculously busy selling selling selling!
a.fewbob
27/4/2020
22:53
Todays up & downs ??I personally think it's because last years results have not been audited yet Why ?? Are they hiding something ?
georgia103
27/4/2020
22:51
Any guesses at what revenue for the next financial year?
a.fewbob
27/4/2020
20:36
Georgia, From your Sharesmagazine post... Revenues: "The company indicated revenues would be approximately £6m" Expectation: £6m The original revenue expectation excluding Covid19 was £6m.. Given they have significant orders, it's shocking the revenue, including Covid19, is not significantly higher... fy2020 revenues of £6m (fy2019 £5.66m). A marginal increase in revenue - Not only contribution due to spike in sales due to Covid19 but also the fact, the revenues also include a full year contribution from MediaMark. Cash: "Cash balances at 31 March were £1.7m." Expectation: £2.6m. Cash: fy2018 £3.85m fy2019 £2.8m H12020 £2.01m fy2020 £1.7m EBITDA: "Pre-exceptional earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to be around £0.25m. Cash balances at 31 March were £1.7m." Expectation: £0.4m Adj EBITDA of £0.25m (fy2019 £0.82m). The expectation was £0.4m, so despite Covid19 and contribution from MediaMark, they missed the Adj EBITDA as well. "this excludes a delayed ‘material new license contract’ which closed in mid-April and will therefore be included in the 2021 fiscal year." They seem to be in a habit of delays in contracts...eg Tristel was originally announced several months ago to start 'late 2019', yet it didn't until last month(see Annual Report below) "‘we continue to operate at full capacity, making and selling as much product as we can as quickly as we can in these difficult times.’" Didn't some posters on here order and have their products delivered within days. So not difficult to obtain, goes against what they are saying. I expect repeat orders have been made... "WELL POSITIONED The board expects the current financial year to show significant growth in revenues and EBITDA as international supply chains improve and the current level of unfulfilled orders declines." Prove is in the results that they are not well positioned. "The management team is working on a number of longer-term product supply contracts and technology licences, including Byotrol24 in the US." They've been seeking a partner in US for months. "While management expects current high levels of demand to ease at some stage during the current financial year" They expect the increased demand to ease during the year. Although a reduced demand continuing - That reduced demand is what's needed to determine future growth... Maybe that's why Finncap wouldn't forecast any. Annual Report - Oct 2019: Delays in contracts: " One such transaction has been completed post year end with Tristel plc, for a surface sanitising product that combines their best-in-class chlorine dioxide chemistry, with our long-lasting germ-killing technology; we expect this product to be launched in late 2019." Seeking a US Partner: " So, after much research and analysis, we have now concluded that we need a US partner either financial or corporate to invest with us to accelerate growth and achieve acceptable returns. We have appointed advisors to assist in finding a suitable partner" • Gross profit increased to £3.61m on turnover of £5.66m (compared to gross profit of £0.69m on turnover of £1.82m in the previous year, as restated for the effects of applying IFRS 15) • EBITDA of £0.82m versus a loss of £1.47m the previous year • Cash and cash equivalents at the year-end of £2.80m compared to £3.85m in the prior year https://byotrolplc.com/wp-content/uploads/2019/10/Byotrol-Annual-Report-FY-2018-19.pdf Finncap - free to register: Expectations: Revenue:£6m, pre-Covid19 Adj EBITDA: £0.4m Net Cash: £2.6m https:finncap.com
sikhthetech
27/4/2020
20:05
1gw## Thank you for your thoughts.
arcadian
27/4/2020
18:19
There could have been some "sell on the news" perhaps. The TU itself was hugely upbeat on outlook in my opinion given the following statements: “We continue to experience exceptional demand…” “…expecting to benefit significantly from a secular shift…” “…expect to generate record sales from products …in the first quarter of the year.” “…also working on a number of longer-term product supply contracts and technology licenses…̶1; “Byotrol has been positioning for such trends for many years and expects them to favour technologies like ours, presenting exceptional growth opportunities for the Group.” “We now expect FY2021 to be one of significant growth in both revenue and EBITDA.” “Our technologies are getting interest from all over the world now. We are increasingly well positioned for further growth post Covid19…”; However, it is difficult to quantify the potential, and to me the TU really feels incomplete without an accompanying broker note from finnCap giving a forecast for this year. Originally I suspect the company and finnCap would have planned to get a finnCap forecast out about now, given the comment in the interims: “We are now working hard on relaunching as a unified company from April 2020 and expect all the recent efforts to then become visible in results and projections.” The interims were before Covid19 became a global issue of course, and so projections have doubtless become more difficult given the huge uncertainty around not only potential this year, but also how supply chain constraints might cap that potential. Nevertheless I think it would be really helpful to investor understanding of byotrol if the company could work with finnCap to get some (reasonably conservative) forecasts into the public domain. Ideally, I would like to see those forecasts provide a breakdown between: - product sales - licence receipts (royalties) - one-off payments I think there are likely to be some revenue recognition issues around some of the deals – in particular how much revenue should be booked up-front for licence agreements with minimum guaranteed payments – and again it would be helpful to get some insight into this. Any forecasts are likely to be based on “done deals” as far as licensing agreements are concerned and so we can hope that they have significant potential for upward revisions as further deals are done. And it may be, if byotrol feels a “big” deal is close, whether on byotrol24 in the US or something else, the company wants to wait until that is announced before working with finnCap on forecasts.
1gw
27/4/2020
17:10
IS it just day traders at play?
arcadian
27/4/2020
16:20
Certainly disappointing to be finishing red after a good update, and on a positive day for the Market.
eeza
27/4/2020
16:16
I`m new here but a good company with good products in demand seems to be tossed around at will. Why? Is it that there are dew shares in the public domain such that a few trades have big effects on the sp? What else?
arcadian
27/4/2020
13:26
This is from Sharesmagazine1039Infection prevention and control company Byotrol (BYOT:AIM) said it continued to experience exceptional demand due to the coronavirus epidemic in its trading update for the year ended 31 March 2020. The shares traded 4% higher at 6.2p.DELAYED MATERIAL CONTRACTThe company indicated revenues would be approximately £6m, but this excludes a delayed 'material new license contract' which closed in mid-April and will therefore be included in the 2021 fiscal year.Pre-exceptional earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to be around £0.25m. Cash balances at 31 March were £1.7m.Chief executive David Traynor commented, 'we continue to operate at full capacity, making and selling as much product as we can as quickly as we can in these difficult times.'WELL POSITIONEDThe board expects the current financial year to show significant growth in revenues and EBITDA as international supply chains improve and the current level of unfulfilled orders declines.The management team is working on a number of longer-term product supply contracts and technology licences, including Byotrol24 in the US.While management expects current high levels of demand to ease at some stage during the current financial year, it also sees businesses and consumers taking 'more proactive responsibility for protecting individuals against infection risk' which will lead to a higher overall level of sustainable demand for anti-microbials.
georgia103
27/4/2020
12:00
Ah, sickbag is back for another pasting I see, though I'm not sure what sparkling new insights are being brought to bear, as the filter has been applied for some months now.
tradertrev
27/4/2020
11:28
Sikh-grow up.
cumnor
27/4/2020
11:02
Given the huge demand for sanitiser and cleaning products and the fact we're in the worst Pandemic for a century, the TU was poor. They only managed £6m revenue and adj EBITDA of £250k against pre-covid expectations of £6m and £400k. That is a huge miss on their expectations. They have been seeking US partners for months and are still talking about. What's happened to Target Trial? £25m for a company with only £6m revenues and £250k adj EBITDA.. really!!! Finncap expectations, as of interims: https://researchlibrary.finncap.com/File/View?file=7094521d-4d9d-42a3-864b-af02865358d5
sikhthetech
27/4/2020
10:43
Interesting to see BYOT on the CNBC ticker this morning.
arcadian
Chat Pages: Latest  374  373  372  371  370  369  368  367  366  365  364  363  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 17:41:23